 And then from donuts to those who might not eat them, you have Bloomberg reporting ozempic copycats. They're raising safety risks for patients. The problem is that the drugs are made by so-called compounding pharmacies, so they don't have to go through that same approval process required by brand names or generic medications. That is your Bloomberg Business Flash. Tom and Paul. Lisa, thanks so much. David Rosenberg up in Toronto. Paul, we've got to stop before Dr. Vinja Murray on this.